OUR SERVICES

Our Process

OUR Products

CONCIERGE SERVICES

In Vitro Testing

In Vivo Testing

Qualification & Tech Transfer

Clinical Testing

Search
Search
Generic filters
Services
Products
Type the name of a target, pathogen, service, assay or catalog number

DISEASE TARGET

IBT has a plethora of reagents, assays or services based on disease targets.

ANIMAL SERVICES

DISTRIBUTION PARTNERS

ARTICLES

Emerging viral threats often stem from viral mutations, which can enhance a virus’s ability to infect hosts, evade immune responses, or become more virulent. An unfortunate example of this is the COVID-19 pandemic, which has fundamentally changed how we live and function as a population. While detrimental, this event has

NEWS

[Rockville, MD, April 2025] A promising new therapeutic is being developed to address the urgent need for effective treatments for Marburg virus disease (MVD), a highly fatal viral infection. Currently, no FDA-approved medical countermeasures (MCMs) exist for the treatment of Marburg virus (MARV). A human monoclonal antibody (mAb) derived from

IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services [Maryland, January 2024] – IBT Bioservices, a renowned figure in the Biocapital region’s life sciences landscape, proudly announces its rebranding from Integrated Biotherapeutics. Effective February 2023, IBT Bioservices unveils a revitalized identity, reinforcing its commitment to excellence in Contract Research

IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the regulatory challenges and opportunities when moving a product from pre-clinical to clinical stage. The live webinar scheduled for Sept. 24, 2020 will feature experts on various aspects of antimicrobial resistance

Search
Generic filters